Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)

Neuro-Oncology

Volumn 14, Issue 3, 2012, Pages 368-380

  Sasayama, Takashi ^a   Nakamizo, Satoshi ^a   Nishihara, Masamitsu ^b   Kawamura, Atsufumi ^c   Tanaka, Hirotomo ^a   Mizukawa, Katsu ^a   Miyake, Shigeru ^a   Taniguchi, Masaaki ^a   Hosoda, Kohkichi ^a   Kohmura, Eiji ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NISHI KOBE MEDICAL CENTER   (Japan)

^c Hyogo Children's Hospital   (Japan)

Author keywords

biomarker, cerebrospinal fluid; IL 10; IL 6; primary CNS lymphoma

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ALPHA;

ARTICLE; BRAIN TUMOR; CANCER GROWTH; CANCER RELAPSE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-10; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84859521316     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor203     Document Type: Article

References (48)

1. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002; 95:1504-1510.
2. Sierra del Rio M, Rousseau A, Soussain C, et al. Primary CNS lymphoma in immunocompetent patients. Oncologist. 2009;14:526-539.
3. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92:261-266. (Pubitemid 30071045)
4. Bernstein M, Berger M. Neuro-Oncology: The Essentials. New York, NY: Thieme Medical Publishers; 2000.
5. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol. 1999;17:554-560. (Pubitemid 29075242)
6. Salles G, Coiffier B. Inherited cytokine response and risk of lymphoma. Lancet Oncol. 2006;7:3-4. (Pubitemid 43025368)
7. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92:1684-1688. (Pubitemid 32939175)
8. Yee C, Biondi A, Wang XH, et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989;74:798-804. (Pubitemid 19208825)
9. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 2005;78:1043-1051. (Pubitemid 41572467)
10. Moore KW, de Waal Malefyt R, Coffman RL. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. (Pubitemid 32368050)
11. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205-218.
12. O'Garra A, Barrat FJ, Castro AG. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008;223:114-131. (Pubitemid 351986180)
13. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7:709-723. (Pubitemid 32707998)
14. Vega MI, Huerta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23:3530-3540. (Pubitemid 38658419)
15. el-Far M, Fouda M, Yahya R. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem. 2004;60:253-258.
16. Nacinović-Duletić A, Stifter S, Dvornik S. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol. 2008;30:230-239. (Pubitemid 351695395)
17. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica. 2001;86: 274-281. (Pubitemid 32291065)
18. Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48:3253-3259. (Pubitemid 351261171)
19. Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr Opin Ophthalmol. 2002;13:411-418. (Pubitemid 35397652)
20. Cassoux N, Merle-Beral H, Lehoang P. Interleukin-10 and intraocularcentral nervous system lymphoma. Ophthalmology. 2001;108: 426-427.
21. Salmaggi A, Eoli M, Corsini E, et al. Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? Ann Neurol. 2000;47: 137-138. (Pubitemid 30033666)
22. Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol. 1997;115: 1157-1160. (Pubitemid 27387952)
23. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137-5144. (Pubitemid 32681546)
24. Jeffery GM, Frampton CM, Legge HM. Cerebrospinal fluid b2-microglobulin levels in meningeal involvement by malignancy. Pathology. 1990;22:20-23. (Pubitemid 20240438)
25. Kersten MJ, Evers LM, Dellemijn PL, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood. 1996;87:1985-1989. (Pubitemid 26068914)
26. Chang CS, Liu HW, Lin SF. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1989;22:132-137.
27. Lee W, Kim SJ, Lee S, et al. Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia. Ann Clin Lab Sci. 2005;35:407-412. (Pubitemid 41579570)
28. Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26:96-105.
29. Gallo P, Sivieri S, Rinaldi L, et al. Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. J Neurol Sci. 1994;126:49-53. (Pubitemid 24305258)
30. De Luca A, Antinori A, Cingolani A, et al. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Haematol. 1995;90:844-849.
31. Intapan PM, Kittimongkolma S, Niwattayakul K, et al. Cerebrospinal fluid cytokine responses in human eosinophilic meningitis associated with angiostrongyliasis. J Neurol Sci. 2008;267:17-21. (Pubitemid 351249897)
32. Saruhan-Direskeneli G, Yentü r SP, Akman-Demir G, et al. Cytokines and chemokines in neuro-Behç et's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol. 2003;145: 127-134. (Pubitemid 37485973)
33. Kashyap RS, Deshpande PS, Ramteke SR, et al. Changes in cerebrospinal fluid cytokine expression in tuberculous meningitis patients with treatment. Neuroimmunomodulation. 2010;17:333-339.
34. Rota E, Bellone G, Rocca P, et al. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006;27:33-39. (Pubitemid 44026855)
35. Bø SH, Davidsen EM, Gulbrandsen P, et al. Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia. 2009;29:365-372.
36. Krzyszkowski T, Dziedzic T, Czepko R. Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res. 2008; 30:294-296. (Pubitemid 351769425)
37. Lee JJ, Kim DH, Lee NY, et al. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol. 2007;137:329-336. (Pubitemid 46650250)
38. Ho JW, Liang RH, Srivastava G. Preferential type 1-1 cytokine gene expressions in peripheral T-cell lymphomas. Hematol Oncol. 1999;17: 117-129. (Pubitemid 30094132)
39. Shen L, Chiang AK, Liu WP, et al. Expression of HLA class I, beta(2)-microglobulin, TAP1 and IL-10 in Epstein-Barr virus-associated nasal NK/T-cell lymphoma: implications for tumor immune escape mechanism. Int J Cancer. 2001;92:692-696. (Pubitemid 32385712)
40. Inagaki A, Ishida T, Ishii T, et al. Clinical significance of serum Th1-, Th2-and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and-10 levels are significant unfavorable prognostic factors. Int J Cancer. 2006;118: 3054-3061.
41. Bhat PV, Jakobiec FA, Papaliodis G. Primary T-cell lymphoma of the retina and cerebellum: immunophenotypic and gene rearrangement confirmation. Am J Ophthalmol. 2009;148:350-360.
42. Lighter J, Tse DB, Kaul A. Hyper interleukin-10 in an HIV-positive child with t-cell lymphoma and candidal sepsis. J Int Assoc Physicians AIDS Care (Chic Ill). 2008;7:228-231.
43. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, et al. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz). 2010;58:131-141.
44. Ozdemir F, Aydin F, Yilmaz M, et al. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL). J Exp Clin Cancer Res. 2004;23:485-488. (Pubitemid 39490634)
45. Camilleri-Broët S, Criniè re E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107:190-196. (Pubitemid 43053543)
46. Raoux D, Duband S, Forest F, et al. Primary central nervous system lymphoma: Immunohistochemical profile and prognostic significance. Neuropathology. 2010;30:232-240.
47. Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol. 1995;155(3):1079-1090.
48. Park YH, Sohn SK, Kim JG, et al. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy. Clin Cancer Res. 2009;15:2107-2115.